Measurements of CRP, PCT, WBC count, neutrophil count and lymphocyte count were performed on blood samples collected at admission to the ICU or, if specific markers were not determined directly on ICU admission, on blood samples taken within 6 hours prior to or after ICU admission. CRP levels were measured with a fully automated enzyme-linked immunoassay using an Aeroset 2.0 analyzer (Abbott Diagnostics, Santa Clara, CA, USA). PCT levels were measured using a commercially available sensitive immunoluminometric assay (LIA sensitive, Brahms AG, Henningsdorf, Germany). WBC count, neutrophil count and lymphocyte count were determined on a Sysmex XE-2100 haematology analyzer (Sysmex Corporation, Kobe, Japan). From September 2012 onwards, CRP levels and PCT levels were measured using a Dimension Vista 1500 analyzer (Siemens Healthcare, the Hague, Netherlands) and WBC count, neutrophil count and lymphocyte count using an Advia 2120i analyzer (Siemens Healthcare, the Hague, Netherlands). The NLCR was calculated by dividing the neutrophil count through the lymphocyte count (normal value 2–4). A PCT level above 100 ng/ml or below 0.02 ng/ml or a CRP level below 6 mg/l or below 3 mg/l (measurement limits) were considered as 101 ng/ml, 0.019 ng/ml, 5 mg/l and 2 mg/l, respectively.
Dimension vista 1500 analyzer
Manufactured by Siemens
Sourced in Germany
The Dimension Vista 1500 analyzer is a laboratory instrument designed for clinical chemistry and immunoassay testing. It is capable of performing a wide range of diagnostic tests on various sample types. The analyzer utilizes advanced technology to provide accurate and reliable results.
Automatically generated - may contain errors
Lab products found in correlation
Aeroset 2.0 analyzer, by Abbott (1 mentions)
Advia 2120i analyzer, by Siemens (1 mentions)
Immulite 2000 analyzer, by Siemens (1 mentions)
Gluco quant glucose hk, by Roche (1 mentions)
Granutest, by Merck Group (1 mentions)
Advia centaur xpt, by Siemens (1 mentions)
Hplc d 100, by Bio-Rad (1 mentions)
Cobas c311 analyzer, by Roche (1 mentions)
Mouse rat fgf 23 c term, by Quidel (1 mentions)
Mouse erythropoietin epo quantikine elisa kit, by R&D Systems (1 mentions)
8 protocols using dimension vista 1500 analyzer
1
Evaluation of Infection Biomarkers in ICU
2
Lipid and Glucose Biomarker Measurement
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The serum total cholesterol concentration was determined via polychromatic endpoint measurement, whereas serum concentrations of HDL cholesterol, LDL cholesterol, and triglycerides were assessed via endpoint measurement with a Dimension Vista 1500 analyzer (Siemens Healthcare Diagnostics, Erlangen, Germany). Concentrations of non-esterified fatty acids (NEFAs) in serum were determined using a commercially available colorimetric enzyme assay (Wako Chemicals GmbH, Neuss, Germany) [22 (link)]. The plasma glucose concentration was assessed via bichromatic endpoint measurement with a Dimension Vista 1500 analyzer. Serum insulin concentrations were determined using a chemiluminescent-immunometric assay with an Immulite 2000 analyzer (Siemens Healthcare Diagnostics, Erlangen, Germany).
3
Genetic Variants in Glucokinase Gene
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Variants in GCK were identified using sequencing. Samples were collected from a population-based cohort of 6,058 individuals both with and without diabetes [50 (link)], 2,930 patients with newly-diagnosed diabetes [51 (link)], patients diagnosed with GCK-MODY [53 (link)] and from a population of 1,146 Danish children [52 (link)]. Individuals were included if they carried one missense GCK variant according to transcript NM_000162 and if a measure of fasting plasma glucose was available. Measures of fasting plasma glucose were examined using a glucose oxidase method (Granutest; Merck, Darmstadt, Germany) in the population based cohort and in samples from patients with known GCK-MODY [50 (link), 53 (link)], an enzymatic hexokinase method (Gluco-quant Glucose/HK, Roche Diagnostics) in newly diagnosed diabetes patients [51 (link)], and using a Dimension Vista® 1500 Analyzer (Siemens, Erlangen, Germany) in children [52 (link)]. Samples were excluded if fasting plasma glucose level exceeded 9 mM.
4
Metabolic Biomarkers in Intervention Study
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Fasting plasma samples were collected on weeks 0, 4, and 8, and used to measure total-cholesterol (Total-C), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), TG, glucose, and insulin levels. Total-C and TG concentrations were measured using enzymatic assays [30 (link)]. Apolipoprotein B (ApoB) was measured by immunonephelometry assay using a Siemens Dimension Vista™ 1500 Analyzer. The HDL-C fraction was obtained after precipitation of VLDL and LDL particles in the infranatant with heparin manganese chloride. LDL-C was calculated with the Friedewald formula [31 (link)]. High-sensitivity C-reactive protein (CRP) levels were measured by immunoassay [32 (link)]. Fasting glycated hemoglobin (HbA1c) was measured in plasma by immunoturbidimetry (Biorad HPLC D-100). Oral glucose tolerance tests (OGTTs) using a 75 g glucose solution were conducted twice during the intervention period (weeks 0 and 8). Blood samples were drawn at −15, 0, 15, 30, 60, 90, and 120 min during the OGTT to assess plasma insulin and glucose levels. Glucose concentrations were enzymatically measured [33 (link)], while insulin concentrations were measured by chemiluminescence (Siemens Advia Centaur XPT). The homeostatic model assessment of insulin resistance (HOMA-IR) index and the Matsuda index were calculated from OGTT values [34 (link),35 (link)].
5
Cholesterol and HbA1c Measurement Protocols
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Total cholesterol was measured using the Dimension Vista 1500 Analyzer (Siemens Healthcare, Erlangen, Germany) with variation coefficients of 4.4% at 2.7 mmol/L and 4.2% at 4.4 mmol/L. HbA1c was measured using the Tosoh HPLC G11 analyzer (Tosoh Bioscience, Inc., San Francisco, CA, USA) with CVs of 3.2% at 32 mmol/mol and 2.5% at 81 mmol/mol. Measurements were performed at Zealand University Hospital, Køge.
6
Hemoglobin and Iron Biomarkers Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Relative hemoglobin values were analyzed based on photometric detection of cyanmethemoglobin. Plasma was collected was analyzed for the following routine parameters: LDH, K+ and Bilirubin (Roche cobas c 311 analyzer). Serum iron levels were measured with Dimension Vista® 1500 analyzer (Siemens). FGF23, cFGF23, and EPO in plasma were detected by Mouse FGF23 DuoSet ELISA (DY2629-05, R&D Systems), Mouse/Rat FGF23 (C-Term) (60-6300, Quidel), and Mouse Erythropoietin/EPO Quantikine ELISA Kit (MEP00B, R&D Systems) according to the manufacturer’s instructions.
7
Comprehensive Blood and Serum Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Blood and serum samples were analyzed by the Department of Laboratory Medicine, Clinical Center, National Institutes of Health in Bethesda, MD. Whole blood complete blood count (CBC) was performed on a Cell Dynn 3700 Analyzer (Abbott Diagnostics, Abbott Park, IL). Serum chemistry analysis was performed on a Siemens Dimension Vista 1500 Analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY).
8
LOCI-based Tumor Marker Assays on Dimension Vista 1500
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Measurements were performed with LOCI™-based tumor marker assays for Dimension™ Vista 1500 analyzer (Siemens Healthcare Diagnostics, Eschborn, Germany). Internal and external quality control specifications were observed according to the guidelines of the German Federal Medical Society (RiliBÄK). 15 The tumor marker assays are part of the routine methods at the Central Laboratory of the University Clinics Bonn. According to the manufacturer's instructions, LOCI™-based assays are heterogeneous sandwich chemiluminescent immunoassays. These assays work with chemibeads, which contain a chemiluminescent dye and sensibeads, which contain a photosensitizer dye. Sandwiches are generated via biotinylated antibodies and chemibeads. After addition of sensibeads, they generate immunocomplexes. Finally, a chemiluminescent reaction is triggered at a wavelength of 680 nm before the final signal will be detected at 612 nm.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!